{"id":"tranexamic-acid-pill","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Thromboembolic events (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tranexamic acid is an antifibrinolytic agent that competitively inhibits the conversion of plasminogen to plasmin, preventing the degradation of fibrin in blood clots. By stabilizing clots and reducing excessive fibrinolysis, it helps control bleeding in conditions characterized by abnormal or excessive fibrin breakdown.","oneSentence":"Tranexamic acid inhibits the breakdown of blood clots by blocking plasminogen activation, thereby reducing fibrinolysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:36.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heavy menstrual bleeding"},{"name":"Prevention of blood loss in surgical procedures"},{"name":"Hemophilia and other bleeding disorders"},{"name":"Traumatic hemorrhage"}]},"trialDetails":[{"nctId":"NCT04448184","phase":"PHASE3","title":"Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-02-16","conditions":"Hematologic Neoplasms","enrollment":662},{"nctId":"NCT06000423","phase":"PHASE4","title":"Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2024-01-23","conditions":"Bleeding, Contraceptive Device; Complications","enrollment":65},{"nctId":"NCT05099276","phase":"PHASE4","title":"Extended Postoperative Oral Tranexamic Acid in Knee Replacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Campbell Clinic","startDate":"2021-12-07","conditions":"Knee Osteoarthritis, Blood Loss, Pain, Postoperative","enrollment":46},{"nctId":"NCT05705336","phase":"PHASE4","title":"Clinical Trial Analyzing the Efficacy of Oral Administration of Tranexamic Acid in Spine Surgery.","status":"COMPLETED","sponsor":"Alejandro Reyes Sánchez","startDate":"2021-01-01","conditions":"Tranexamic Acid (TXA), Prospective Study, Evidence-based Medicine","enrollment":60},{"nctId":"NCT05594186","phase":"NA","title":"Nonsurgical Management of Cesarean Scar Niche Related Abnormal Uterine Bleeding","status":"COMPLETED","sponsor":"Saudi German Hospital - Madinah","startDate":"2019-03-01","conditions":"Intermenstrual Bleeding","enrollment":158},{"nctId":"NCT05518279","phase":"PHASE3","title":"Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2019-09","conditions":"Hip Fractures, Blood Loss","enrollment":""},{"nctId":"NCT02578901","phase":"PHASE3","title":"American Trial Using Tranexamic Acid in Thrombocytopenia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-06","conditions":"Thrombocytopenia","enrollment":330},{"nctId":"NCT02825719","phase":"PHASE4","title":"Ulipristal Use in Chinese Population","status":"TERMINATED","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2015-12-02","conditions":"Fibroid","enrollment":31},{"nctId":"NCT03027973","phase":"PHASE1","title":"Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2020-01","conditions":"Heavy Menstrual Bleeding","enrollment":""},{"nctId":"NCT03585179","phase":"PHASE3","title":"Oral and Topical Tranexamic Acid for the Treatment of Melasma","status":"UNKNOWN","sponsor":"Centro Dermatológico Dr. Ladislao de la Pascua","startDate":"2018-08-01","conditions":"Melasma, Chloasma, Melanosis","enrollment":120},{"nctId":"NCT01428713","phase":"NA","title":"Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2011-08","conditions":"Menorrhagia","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tranexamic Acid Pill","genericName":"Tranexamic Acid Pill","companyName":"Henry Ford Health System","companyId":"henry-ford-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tranexamic acid is a medication used to treat conditions such as heavy menstrual bleeding, intermenstrual bleeding, menorrhagia, and knee osteoarthritis-related blood loss. It is administered as a pill, often compared to a placebo in clinical trials, and its mechanism of action is related to its ability to inhibit the breakdown of fibrin clots, as indicated by its entry in ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}